Henry Schein
HSIC
$75.53
+2.27%
Henry Schein Inc is a solutions company for healthcare professionals, operating in the medical distribution industry by providing healthcare equipment, products, and services to office-based dental and medical practitioners. The company is a leading global distributor, distinguished by its integrated business model that combines distribution with value-added services, specialty products, and technology solutions. The current investor narrative revolves around the company's recovery from a significant cybersecurity incident that disrupted operations in late 2023, with recent financial results showing a return to revenue growth and margin stabilization, sparking debate on the sustainability of its recovery trajectory and the long-term impact on its competitive position.…
HSIC
Henry Schein
$75.53
HSIC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Henry Schein's 12-month outlook, with a consensus price target around $98.19 and implied upside of +30.0% versus the current price.
Average Target
$98.19
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$60 - $98
Analyst target range
The stock is covered by 7 analysts, with recent institutional ratings showing a mix of views: 3 Outperform/Overweight, 3 Neutral/Market Perform, and 1 Underweight, indicating a cautiously optimistic but divided consensus. The average revenue estimate for the coming period is $15.30 billion, with a tight EPS estimate range between $6.75 and $6.85, but a specific consensus price target is not provided in the data, limiting the calculation of implied upside. The target price range and recent rating actions are not fully detailed, but the upgrade from Baird to 'Outperform' in late February 2026 suggests some analysts see improving fundamentals, while the maintained 'Underweight' from Morgan Stanley indicates persistent concerns, leading to a wide dispersion of views that reflects high uncertainty around the company's recovery path.
Bulls vs Bears: HSIC Investment Factors
The bull and bear cases for HSIC are tightly balanced, with the evidence currently leaning slightly bearish in the near term due to deteriorating price momentum and persistent margin challenges. The bull thesis is anchored on a compelling forward earnings recovery priced at a 12.6x P/E and strong cash flow, while the bear case focuses on the stock's failure to hold recent highs and its premium trailing valuation. The single most important tension in the investment debate is the market's expectation for earnings normalization (forward P/E of 12.6x) versus the reality of still-depressed and volatile profitability (net margin of 2.94%). The resolution of this gap—whether HSIC can deliver the implied earnings growth to justify its forward multiple—will determine the stock's direction.
Bullish
- Strong Forward P/E Discount: The forward P/E of 12.6x is nearly half the trailing P/E of 23.1x, indicating the market expects a significant earnings recovery. This valuation is also below the stock's own historical P/E range of 17x-26x, suggesting potential upside as operations normalize.
- Robust Free Cash Flow Generation: The company generated $561 million in TTM free cash flow, demonstrating strong underlying cash generation despite the cyberattack. This provides financial flexibility for debt service, investments, and shareholder returns, supporting a stable recovery.
- Steady Sequential Revenue Recovery: Quarterly revenue grew from $3.168B in Q1 2025 to $3.437B in Q4 2025, culminating in a 7.71% YoY growth for Q4. This clear upward trajectory confirms the business is recovering lost sales and customer confidence post-incident.
- Healthy Balance Sheet & ROE: A debt-to-equity ratio of 1.14 is manageable, and a Return on Equity of 12.27% indicates the company is efficiently generating profits from shareholder capital. This financial stability underpins the recovery thesis.
Bearish
- Recent Price Momentum Breakdown: The stock is down 7.82% over the past month and 3.75% over three months, underperforming the S&P 500. This suggests the initial recovery rally has stalled, potentially due to profit-taking or renewed concerns about the pace of normalization.
- Low & Volatile Net Margins: Q4 2025 net margin was only 2.94%, and it has fluctuated between 2.65% and 3.47% over the last four quarters. This highlights the business's low-margin profile and sensitivity to operational disruptions, limiting earnings power.
- High Short Interest & Analyst Skepticism: A short ratio of 3.34 indicates significant bearish bets against the stock. Furthermore, analyst consensus is divided, with 3 Neutral and 1 Underweight rating, reflecting persistent uncertainty about the long-term impact of the cyberattack.
- Valuation Premium on Trailing Metrics: A trailing P/E of 23.1x and a PEG ratio of 3.22 are elevated for a low-growth distributor. This premium pricing leaves little room for error; any earnings disappointment could trigger multiple compression.
HSIC Technical Analysis
The stock is in a recovery phase from a significant downturn, with a 1-year price change of 6.77% but a 3-month decline of -3.75%, indicating recent consolidation after a strong rebound. Currently trading at a price of $73.94, it sits approximately 41% above its 52-week low of $60.56 but still 17% below its 52-week high of $89.29, positioning it in the lower-middle of its annual range, suggesting the recovery has stalled and the stock is searching for a new catalyst. Recent momentum has turned negative, with a 1-month price change of -7.82%, which sharply contrasts with the positive 6-month change of 10.31%, signaling a significant short-term pullback that may represent profit-taking or renewed concerns after the initial post-cyberattack recovery rally. The stock's beta of 0.88 indicates it is 12% less volatile than the broader market, which is typical for a stable distribution business but noteworthy given its recent operational disruptions. Key technical support is anchored at the 52-week low of $60.56, while major resistance lies at the 52-week high of $89.29; a sustained break above the recent highs near $83 could signal a resumption of the recovery trend, while a breakdown below $70 would suggest the rally has failed.
Beta
0.88
0.88x market volatility
Max Drawdown
-17.8%
Largest decline past year
52-Week Range
$61-$89
Price range past year
Annual Return
+20.5%
Cumulative gain past year
| Period | HSIC Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | -0.3% |
| 3m | -4.4% | -2.0% |
| 6m | +19.6% | +3.5% |
| 1y | +20.5% | +36.2% |
| ytd | -1.7% | -0.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HSIC Fundamental Analysis
Revenue growth has resumed following the cyberattack disruption, with Q4 2025 revenue of $3.437 billion representing a 7.71% year-over-year increase, and sequential quarterly revenue has grown from $3.168 billion in Q1 to the Q4 figure, indicating a steady recovery trajectory. The company is profitable, with Q4 2025 net income of $101 million and a net margin of 2.94%, though gross margin for the quarter was 28.92%, which has been relatively stable around the 29% level seen in recent quarters, reflecting the low-margin nature of the distribution business. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.14, and the company generated substantial free cash flow of $561 million over the trailing twelve months, alongside a return on equity of 12.27%, indicating it is generating adequate cash to fund operations and service its debt while delivering acceptable returns to shareholders.
Quarterly Revenue
$3.4B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$561000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HSIC Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 23.11x, while the forward P/E is significantly lower at 12.60x, indicating the market expects a substantial recovery in earnings over the next year. Compared to sector averages, the stock's trailing P/E of 23.11x and Price/Sales ratio of 0.70x are not directly comparable without industry benchmarks, but the forward P/E discount suggests the market is pricing in normalized earnings post-recovery. Historically, the current trailing P/E of 23.11x is below the stock's own historical range seen in recent quarters, which has fluctuated between approximately 17x and 26x over the past two years, suggesting the valuation is not stretched and may reflect lingering uncertainty from the cyber incident.
PE
23.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 15x~136x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HSIC's primary financial risk is its thin and volatile profitability, with net margins compressed to 2.94% in Q4 2025. The company operates in a low-margin distribution business, making it highly sensitive to any cost inflation or operational inefficiencies, as evidenced by the significant EBITDA impact of the cyberattack. While free cash flow of $561 million is robust, a debt-to-equity ratio of 1.14 introduces leverage risk if earnings recovery falters, potentially straining financial flexibility.
Market & Competitive Risks: The stock trades at a trailing P/E of 23.1x, a premium for a company with a PEG ratio of 3.22, indicating high growth expectations are already priced in. This creates valuation compression risk if earnings growth disappoints. Competitive risks are heightened post-cyberattack, as customers may have diversified suppliers, threatening HSIC's market share. The stock's beta of 0.88 suggests it is less volatile than the market, but its recent 1-month underperformance (-7.82% vs. SPY's -4.28%) shows it carries unique, company-specific risk.
Worst-Case Scenario: The worst-case scenario involves a failure of the earnings recovery, where cybersecurity remediation costs remain elevated, margins fail to improve, and market share is permanently lost to competitors. This could trigger analyst downgrades and a re-rating to the lower end of its historical P/E range. A realistic downside could see the stock retesting its 52-week low of $60.56, representing a potential loss of approximately -18% from the current price of $73.94. A breach of this level could lead to further declines towards the $55-$60 range, aligning with a bear-case P/E multiple on depressed earnings.